aTyr Pharma, Inc. Cash Flow Conversion Efficiency
aTyr Pharma, Inc. cash flow conversion efficiency. Based on the latest financial reports, aTyr Pharma, Inc. (ATYR) has a cash flow conversion efficiency ratio of -0.181x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.20 Million) by net assets ($67.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of aTyr Pharma, Inc. (2012–2025)
Cash flow conversion efficiency of aTyr Pharma, Inc. from 2012 to 2025. This chart illustrates how aTyr Pharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View aTyr Pharma, Inc. stock price for real-time trading data and today's change.
aTyr Pharma, Inc. Cash Flow Conversion Ratio Explained
aTyr Pharma, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
aTyr Pharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of aTyr Pharma, Inc. ranked by their cash flow conversion efficiency. Also see ATYR market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thinkific Labs Inc
TO:THNC
|
-0.004x |
|
Seanergy Maritime Holdings Corp
F:RHSR
|
0.037x |
|
Namsun Alumini
KO:008350
|
-0.017x |
|
Winsome Resources Ltd
AU:WR1
|
-0.050x |
|
Inspired Entertainment Inc
NASDAQ:INSE
|
-0.179x |
|
51 TALK ONL. SP.ADR A 60
F:C4G0
|
N/A |
|
vTv Therapeutics Inc
NASDAQ:VTVT
|
-0.029x |
|
Guerbet S. A.
PA:GBT
|
0.188x |
Annual Cash Flow Conversion Efficiency for aTyr Pharma, Inc. (2012–2025)
The table below shows the annual cash flow conversion efficiency of aTyr Pharma, Inc. from 2012 to 2025. Review aTyr Pharma, Inc. free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $67.29 Million | $-61.99 Million | -0.921x | +6.93% |
| 2024-12-31 | $69.83 Million | $-69.12 Million | -0.990x | -169.55% |
| 2023-12-31 | $90.47 Million | $-33.22 Million | -0.367x | +37.51% |
| 2022-12-31 | $71.28 Million | $-41.89 Million | -0.588x | -93.87% |
| 2021-12-31 | $109.13 Million | $-33.08 Million | -0.303x | +37.63% |
| 2020-12-31 | $31.48 Million | $-15.30 Million | -0.486x | +48.94% |
| 2019-12-31 | $21.03 Million | $-20.01 Million | -0.952x | -3.11% |
| 2018-12-31 | $33.65 Million | $-31.06 Million | -0.923x | -39.99% |
| 2017-12-31 | $64.25 Million | $-42.36 Million | -0.659x | +21.66% |
| 2016-12-31 | $62.80 Million | $-52.86 Million | -0.842x | -163.17% |
| 2015-12-31 | $115.05 Million | $-36.80 Million | -0.320x | -227.53% |
| 2014-12-31 | $-91.01 Million | $-22.82 Million | 0.251x | -4.27% |
| 2013-12-31 | $-66.08 Million | $-17.31 Million | 0.262x | -97.10% |
| 2012-12-31 | $-1.26 Million | $-11.38 Million | 9.030x | -- |
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinica… Read more